Skip to content

Study · Ex vivo tissue · rat · 1986

1 result

Characterization of a specific, high affinity [3H]arginine8 vasopressin-binding site on liver microsomes from different strains of rat and the role of magnesium.

Gopalakrishnan V, Triggle CR, Sulakhe PV, McNeill JR

Endocrinology1 Mar 1986Cited by 14 (Europe PMC)

PMID3004905 (opens in a new tab)DOI10.1210/endo-118-3-990 (opens in a new tab)PepBankPUB-03004905
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In rat liver microsomes, oxytocin competitively inhibited specific [3H]AVP binding with a Ki of 41.4 nM, weaker than AVP at 0.19 nM.

    In plain wordsIn lab tests on rat liver membranes, oxytocin blocked vasopressin binding, but much more weakly than vasopressin itself.

    Peptide
    Oxytocin
    Outcome
    Not applicableCompetitive inhibition of [3H]AVP binding (Ki)
    Study

    ratn: not reported in source

    Rat liver microsomes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Ki
    41.4 nM
    [3H]AVP binding, rat liver microsomes

    Source sentences

    Summary
    Competitive inhibition of specific [3H]AVP binding by unlabeled AVP and related peptides showed the following Ki values: AVP, 0.19 nM; LVP, 1.7 nM; oxytocin, 41.4 nM
    1 context sentence
    Summary · context
    A single class of high affinity, low capacity, specific binding sites for [3H]arginine8 vasopressin (AVP) has been characterized in a plasma membrane-enriched microsomal fraction of the rat liver.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.